Latisse UK updates

This is an update of the clinical evidence supporting the use of bimatoprost (brand name: Latisse or Lumigan) for various different indications.

In September 2012 a paper was published by Dr Glaser in California in which Latisse users were followed for one year.

They found that after one year of treatment the patient satisfaction rate remained high and very few had side effects, the only recorded ones in this patient group being inflammation at the site of application.

A separate paper followed individuals that had underwent chemotherapy for breast cancer.

Patients were allocated into two groups - one used Latisse straight after chemotherapy and the other used a placebo. The Latisse group noticed far quicker eyelash regrowth. After 6 months the placebo group changed to Latisse and their eyelash growth rapidly increased as well.

There was increased irritation in users post chemotherapy in both the Latisse group and the placebo.

To read more articles visit: https://www.mylash.org/about/articles/

Comments

Popular posts from this blog

Stylist reviews Mylash

Time to anti-age your eyelashes

Beauty insider